Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients with advanced urothelial cancer

    NEXT STORY
    Global X-Ray Detectors Industry
    PREV STORY
    Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19

    author_avatar
    NASDAQ Market News

    Active Biotech AB Interim report January – June 2016

    LUND, Sweden, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Laquinimod The clinical trials CONCERTO, ARPEGGIO ...

    author_avatar
    NASDAQ Market News

    Ascendis Pharma A/S Reports Full-Year 2019 Financial Results

    author_avatar
    NASDAQ Market News